Alpha Cognition Launches Breakthrough ZUNVEYL for Mild to Moderate Alzheimer’s

Alpha Cognition, a biopharmaceutical company focused on neurodegenerative diseases, has officially launched ZUNVEYL, a new treatment for individuals with mild to moderate Alzheimer’s disease. 

This commercial launch represents a key step in the company’s efforts to deliver innovative and accessible treatment options to patients and their caregivers.

The company has established a strong commercial infrastructure, with a nationwide salesforce now actively engaging healthcare providers to support access to ZUNVEYL. The sales strategy has been tailored to meet the specific needs of the long-term care sector, which is the largest market segment for Alzheimer’s disease and is estimated to be worth around $2 billion.

Alpha Cognition’s commercial team includes experienced professionals with significant expertise in the Alzheimer’s space and long-term care. On average, the sales representatives bring 16 years of industry experience and over a decade of focus on the long-term care market. This experienced team is working to drive the uptake of ZUNVEYL from the outset.

ZUNVEYL offers an alternative treatment option for patients with limited choices and is available in three doses: 5 mg, 10 mg, and 15 mg. The medicine is now accessible through pharmacies across the country via prescription. 

The company is also working closely with healthcare providers, payers, and caregivers to support education and access to the new treatment.

With this launch, Alpha Cognition aims to improve the treatment landscape for Alzheimer’s disease and offer a new option for those affected by the condition.